USA flag logo/image

An Official Website of the United States Government

IGF::OT::IGF OTHER FUNCTIONS SBIR PHASE II, TOPIC 22, DEVELOPMENT OF…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
N44CO120095
Solicitation Year:
2012
Solicitation Topic Code:
NCI
Solicitation Number:
Small Business Information
BIOTEX, INC.
8058 EL RIO ST HOUSTON, TX -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2012
Title: IGF::OT::IGF OTHER FUNCTIONS SBIR PHASE II, TOPIC 22, DEVELOPMENT OF ALTERNATIVE AFFINITY CAPTURE REAGENTS FOR CANCER PROTEOMICS RESEARCH
Agency: HHS
Contract: N44CO120095
Award Amount: $749,996.00
 

Abstract:

Thousands of antibodies are produced every year by commercial companies. However, many of these antibodies are known to be poorly characterized and suboptimal across applications. Polyclonal antibodies lack the reproducibility of monoclonal antibodies. Theproduction of monoclonal antibodies is expensive and may take months. Even after production, a monoclonal antibody may not be specific for the target of interest, may not work in the needed assay, or could not be used in combination with other antibodiesdue to competition for overlapping binding domains. As such, the high cost associated with producing even small quantities of monoclonal antibodies represents a large barrier to cost-effective reagents for proteomic technology research and clinical adaptation. This project utilizes a new tool, massively parallel selection of DNA aptamers to rapidly identify high-affinity ligands to hundreds or even thousands of protein targets simultaneously. In this Phase II SBIR contract, we will utilize our platform to select aptamers to at least 75 important cancer biomarker proteins and characterize the new reagents for affinity and specificity. We will also demonstrate their performance in a number of common applications. The developed reagents will have tremendous value to the research community and potential to alleviate human suffering due to cancer.

Principal Investigator:

George Jackson
713-741-0111
BILL@BIOTEXMEDICAL.COM

Business Contact:

George Jackson
713-741-0111
BILL@BIOTEXMEDICAL.COM
Small Business Information at Submission:

BIOTEX, INC.
BIOTEX, INC. HOUSTON, TX 77054-4104

EIN/Tax ID: 742824041
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No